These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 27716620)

  • 1. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
    Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic investigation into circulating microRNA 197-3p in sera from patients affected by malignant pleural mesothelioma and workers ex-exposed to asbestos.
    Di Mauro G; Frontini F; Torreggiani E; Iaquinta MR; Caselli A; Mazziotta C; Esposito V; Mazzoni E; Libener R; Grosso F; Maconi A; Martini F; Bononi I; Tognon M
    Sci Rep; 2023 Apr; 13(1):6501. PubMed ID: 37081052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating microRNA-197-3p as a potential biomarker for asbestos exposure.
    Frontini F; Bononi I; Torreggiani E; Di Mauro G; Mazzoni E; Stendardo M; Boschetto P; Libener R; Guaschino R; Grosso F; Guerra G; Martini F; Tognon M
    Sci Rep; 2021 Dec; 11(1):23955. PubMed ID: 34907223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.
    Matboli M; Shafei AE; Azazy AE; Reda M; El-Khazragy N; Nagy AA; Ali MA; Sobhi M; Abdel-Rahman O
    Biomark Med; 2018 Feb; 12(2):129-139. PubMed ID: 29338319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
    Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
    Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNAs dysregulation in human malignant pleural mesothelioma.
    Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
    J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
    Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
    PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis.
    Micolucci L; Akhtar MM; Olivieri F; Rippo MR; Procopio AD
    Oncotarget; 2016 Sep; 7(36):58606-58637. PubMed ID: 27259231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma.
    Matboli M; Shafei AE; Ali MA; Gaber AI; Galal A; Tarek O; Marei M; Khairy E; El-Khazragy N; Anber N; Abdel-Rahman O
    J Cell Biochem; 2019 Mar; 120(3):3203-3211. PubMed ID: 30362153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
    Sato H; Soh J; Aoe K; Fujimoto N; Tanaka S; Namba K; Torigoe H; Shien K; Yamamoto H; Tomida S; Tao H; Okabe K; Kishimoto T; Toyooka S
    Int J Oncol; 2019 Jun; 54(6):2139-2148. PubMed ID: 30942424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
    Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma.
    Weber DG; Gawrych K; Casjens S; Brik A; Lehnert M; Taeger D; Pesch B; Kollmeier J; Bauer TT; Johnen G; Brüning T
    Dis Markers; 2017; 2017():9280170. PubMed ID: 28321148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
    J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.
    Jiménez-Ramírez C; Gilbert Weber D; Aguilar-Madrid G; Brik A; Juárez-Pérez CA; Casjens S; Raiko I; Brüning T; Johnen G; Cabello-López A
    PLoS One; 2022; 17(10):e0275936. PubMed ID: 36240245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma.
    Kirschner MB; Cheng YY; Badrian B; Kao SC; Creaney J; Edelman JJ; Armstrong NJ; Vallely MP; Musk AW; Robinson BW; McCaughan BC; Klebe S; Mutsaers SE; van Zandwijk N; Reid G
    J Thorac Oncol; 2012 Jul; 7(7):1184-91. PubMed ID: 22617246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
    Andersen M; Grauslund M; Ravn J; Sørensen JB; Andersen CB; Santoni-Rugiu E
    J Mol Diagn; 2014 Jul; 16(4):418-30. PubMed ID: 24912849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study.
    Weber DG; Brik A; Casjens S; Burek K; Lehnert M; Pesch B; Taeger D; Brüning T; Johnen G;
    BMC Res Notes; 2019 Feb; 12(1):77. PubMed ID: 30744695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.